Maze Therapeutics raises $191 mln
Maze Therapeutics said Feb. 28 that it raised $191 million in funding led by Third Rock Ventures and ARCH Venture Partners. Also participating were GV, Foresite Capital, Casdin Capital, Alexandria Venture Investments and other undisclosed investors. Maze, of San Francisco, develops medicines based on genetic modifiers.
28 February 2019•4 mins read
